Black checkmark with a sparkle and a curved line underneath on a white background.
Company

REVVITY, INC.

Ticker
RVTY
Sector
Industry
Report date
November 11, 2026
Valye AI Score

88

Very high visibility
Recent developments
Recent developments summary

Recent developments focus on the company's Q3 2026 financial results and earnings call, highlighting life sciences strength and positive business momentum amid market conditions.

Recent developments:
  • REVVITY reported third quarter 2026 financial results with net income of $62.3 million and EPS of $0.56 as of October 4, 2026, reflecting profitability and operational execution [S2].
  • The company held a Q3 2026 earnings call discussing business performance, life sciences segment strength, and market outlook [N2][N5][N8].
  • Market commentary noted strength in chipmakers and related sectors, supporting broader market gains including companies like REVVITY [N1][N3][N4].
  • REVVITY's Q3 earnings were highlighted for beating expectations on life sciences strength, with an upward view for 2026 [N7].
  • The company’s financial results and earnings call transcripts were widely covered by Nasdaq, providing detailed insights into business trends and execution [N6][N5].
Overview

REVVITY, INC. is a company operating primarily in the life sciences and diagnostics sectors. It provides products and services related to molecular cloning, diagnostics, and research and development data solutions. The company reports financial results quarterly and annually through SEC filings, with recent disclosures showing solid liquidity and profitability metrics. Its business segments include Life Sciences and Diagnostics, serving global markets.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for RVTY

Bull case model:

The company demonstrates operational strength through consistent profitability and liquidity, supported by a diversified portfolio in life sciences and diagnostics. Recent earnings calls and financial results indicate business momentum and market acceptance of its solutions. Continued innovation and expansion in molecular cloning and diagnostics could enhance its market position.

Bear case model:

Risks include potential headwinds in key geographic markets such as China, competitive pressures in the diagnostics and life sciences sectors, and exposure to macroeconomic factors affecting research and healthcare spending. Execution risks related to product development and market adoption may also impact business performance.

Moat:

REVVITY's moat is supported by its specialized offerings in life sciences and diagnostics, including proprietary technologies and solutions that cater to research and clinical needs. Its presence in multiple geographic regions and diversified product lines contribute to competitive positioning. The company's investments in innovation and intellectual property provide barriers to entry for competitors.

Risks overview
Risks summary
Geographic and competitive risks combined with regulatory and macroeconomic factors represent the primary challenges to the company's business stability.
Risks details:

• Geographic Market Risks: The company faces challenges in certain regions, including China, which may affect revenue growth and operational stability.
• Competitive Pressure: The life sciences and diagnostics markets are competitive, with rapid technological changes and new entrants potentially impacting market share.
• Macroeconomic and Regulatory Risks: Changes in healthcare regulations, funding for research, and economic conditions could influence demand for the company's products and services.

FINAL FORECAST FOR RVTY

Final take one line
REVVITY, INC. exhibits very high visibility with comprehensive financial disclosures and extensive recent news coverage highlighting operational strength in life sciences and diagnostics.
Final take 12 to 24 month view

Business trends: Continued strength in life sciences segment and operational profitability amid evolving market conditions.
Execution milestones: Delivery of quarterly financial results, earnings calls, and maintaining liquidity ratios above 2.5.
Key risks: Geographic market challenges, competitive pressures, and regulatory environment uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

88
LLM visibility overview
LLM Visibility known facts
  • REVVITY, INC. operates in the life sciences and diagnostics sectors, with business segments including Life Sciences and Diagnostics.
  • As of the quarter ended October 4, 2026, the company reported cash and cash equivalents of $592.8 million and current assets of approximately $1.86 billion.
  • Current liabilities as of October 4, 2026, were approximately $701.5 million, resulting in a current ratio of 2.65 and a cash ratio of 0.85, indicating liquidity strength.
  • The company reported net income of $62.3 million for the quarter ended October 4, 2026, with basic and diluted earnings per share of $0.56.
  • Annual revenue reported for fiscal year 2022 was approximately $741.2 million.
  • Recent news coverage includes multiple reports and transcripts from the Q3 2026 earnings call, highlighting life sciences strength and financial results.
  • The company has disclosed financial figures and operational updates in SEC filings including the 10-K filed on February 24, 2026, and the 10-Q filed on November 10, 2026.
  • Recent developments include earnings call highlights and financial results for Q3 2026, with commentary on business strength and market conditions.
  • Liquidity ratios and financial metrics are derived from SEC XBRL companyfacts for the latest available period and are provided for informational purposes only.
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-02-24 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-04 | www.nasdaq.com | Stocks Finished Mostly Higher on Chipmaker Strength | https://www.nasdaq.com/articles/stocks-finished-mostly-higher-chipmaker-strength
  • N2 | 2026-11-04 | www.nasdaq.com | Revvity Q3 Earnings Call Highlights | https://www.nasdaq.com/articles/revvity-q3-earnings-call-highlights
  • N3 | 2026-11-03 | www.nasdaq.com | Stocks Rebound as Crude Oil Prices Fall and Chipmakers Recover | https://www.nasdaq.com/articles/stocks-rebound-crude-oil-prices-fall-and-chipmakers-recover
  • N4 | 2026-11-03 | www.nasdaq.com | Stocks Supported by Strength in Chipmakers | https://www.nasdaq.com/articles/stocks-supported-strength-chipmakers
  • N5 | 2026-11-03 | www.nasdaq.com | Revvity (RVTY) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/revvity-rvty-q3-2026-earnings-call-transcript
  • N6 | 2026-11-03 | www.nasdaq.com | Revvity, Inc. Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/revvity-inc-reports-third-quarter-2026-financial-results
  • N7 | 2026-11-03 | www.nasdaq.com | RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up | https://www.nasdaq.com/articles/rvty-q3-earnings-beat-estimates-life-sciences-strength-26-view
  • N8 | 2026-11-03 | www.nasdaq.com | Revvity Q3 26 Earnings Conference Call At 7:30 AM ET | https://www.nasdaq.com/articles/revvity-q3-26-earnings-conference-call-7-30-am-et
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine